TPWA
NBIX icon

Twin Peaks Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-137
Closed -$18K – 1474
2026
Q1 		$18K Buy
+137
New +$18.2K ﹤0.01% 763
2025
Q3 		– Sell
-126
Closed -$16.2K – 1400
2025
Q2 		$16.2K Buy
+126
New +$14.4K 0.01% 681

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Twin Peaks Wealth Advisors's NBIX Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 137 shares — an estimated $18K sold.

Twin Peaks Wealth Advisors first reported a position in NBIX in Q2 2025 and held it in 2 quarters. The position peaked at $18K in Q1 2026. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 137 Neurocrine Biosciences shares in Q2 2026, an estimated $18K.
  • Twin Peaks Wealth Advisors first reported a position in Neurocrine Biosciences in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Neurocrine Biosciences position peaked at $18K in Q1 2026.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.